Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
Retatrutide
3–7 days most of the EU · 8–14 Nordics/Baltics
Standard EU from €4.99 (RO) · core EU GLS €17.99 · Nordics/Baltics €12.99–€13.99 · Same-day dispatch before 14:00 CET on weekdays · Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
€200.00 away from free shipping over €200. Under that, standard EU shipping is €17.99 (GLS, most of the EU).
How Paysera and SEPA work
- Pay — approve a SEPA transfer in your own bank via Paysera’s hosted page, or send a manual SEPA transfer using the IBAN we email you.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders placed before 14:00 CET on a weekday typically ship the same day.
Card payments are not currently offered. There is no card processor on this checkout.
Free shipping on orders over €200
Retatrutide is a novel triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. This multi-receptor approach has generated significant research interest in metabolic studies. Triple hormone receptor agonism (GIP/GLP-1/Glucagon) Metabolic pathway modulation research Energy homeostasis and body composition studies For research purposes only.
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €44.49 | €44.49 | -- |
| 3+ | €42.27 | €126.80 | 5% off |
| 5+Most Popular | €40.04 | €200.21 | 10% off |
| 10+ | €37.82 | €378.16 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
Recommended: BAC water · stable for 21 days at 2-8°C once mixed.
When This Product May Not Suit Your Research
- ⚠If your research requires a commercially available pharmaceutical — Retatrutide is still in clinical trials (Phase III).
- ⚠If your protocol needs a compound with an established safety profile — long-term safety data is still being collected.
- ⚠If your lab cannot maintain -20°C storage for reconstituted solutions — stability data at higher temperatures is limited.
Published laboratory reports are available for selected lots. Check each report for its result and stated method. For research purposes only.
View report #212146 on janoshik.com →
24h dispatch, EU-wide shipping from €4.99
Supplier batch specification on every product; independent Janoshik report on selected lots
About Retatrutide
What Is Retatrutide?
Retatrutide (CAS 2381089-83-2; also known as LY3437943) is a 39-amino acid synthetic peptide engineered as a triple agonist of three distinct metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG). Its structure carries a C-20 fatty diacid conjugated to the peptide backbone, extending the plasma half-life. CertaPeptides supplies retatrutide in lyophilized powder form from 2mg through 60mg per vial.
CAS: 2381089-83-2. Alternate identifier: LY3437943. Molecular weight: 4703.5 g/mol. Receptor-engagement profile: GIP-R, GLP-1R, and GCG-R simultaneously.
How Retatrutide Is Studied in the Literature
Retatrutide is characterised in the published peptide-research literature primarily through its triple-receptor pharmacology and its effects in preclinical metabolic models. The notes below describe the research context in which the molecule is investigated. They are reported for scientific background only and are not claims about what CertaPeptides' research compound will do in any individual.
Body-composition and energy-expenditure research
In preclinical and in-vitro metabolic models, retatrutide is studied for its effects on body composition, adiposity, and energy-expenditure pathways. Researchers investigate how simultaneous engagement of GIP-R, GLP-1R, and GCG-R modulates these processes relative to single- and dual-receptor agonists.
Glucose-regulation pathway research
Retatrutide is also investigated in metabolic models for its role in glucose-regulation and incretin signalling pathways, including the dose-dependent receptor pharmacology that underlies its activity at the three target receptors.
Within the Incretin Class — How Retatrutide Differs
Retatrutide is studied alongside two other research peptides in the same metabolic class: semaglutide (single GLP-1R agonist) and tirzepatide (dual GIP/GLP-1R agonist). The three differ structurally and mechanistically in ways that shape how each compound is studied:
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor engagement | GLP-1R (single) | GIP-R + GLP-1R (dual) | GIP-R + GLP-1R + GCG-R (triple) |
| Amino acid count | 31 | 39 | 39 |
| Molecular weight | 4113.58 Da | 4813.5 Da | 4703.5 Da |
| Unique mechanistic element | Fatty-acid modification extends half-life at GLP-1R | Imbalanced biased agonism favouring GIP-R | Glucagon-receptor engagement adds hepatic glucose output & energy expenditure signals |
The glucagon-receptor arm is the distinguishing feature: neither semaglutide nor tirzepatide activates GCG-R. In research contexts this is of interest because glucagon agonism increases hepatic glucose output and thermogenesis, adding an energy-expenditure component not present in the single- or dual-agonist compounds. Researchers comparing the three frequently reference the GLP-1 class comparison overview and the molecular-level triple-receptor mechanism overview.
Research Areas Where Retatrutide Is Studied
- GIP, GLP-1, and glucagon receptor pharmacology — comparative in vitro binding and signalling assays
- Preclinical metabolic models of body composition and energy expenditure
- Comparative studies against single- and dual-agonist compounds (semaglutide, tirzepatide)
- Lipid metabolism and hepatic glucose-output pathways (glucagon-arm specific)
- Formulation and stability research for long-acting peptide analogues
Specifications
| CAS Number | 2381089-83-2 |
| Alternate identifier | LY3437943 |
| Molecular Weight | 4703.5 g/mol |
| Receptor profile | Triple agonist: GIP-R / GLP-1R / GCG-R |
| Purity | ≥ 98% (supplier batch spec) |
| Physical Form | Lyophilized (freeze-dried) powder in sealed glass vial |
| Available Sizes | 2mg, 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg |
Storage
Lyophilized powder: −20°C for long-term storage. 2–8°C for short-term use before reconstitution.
Reconstituted: 2–8°C, use within 4 weeks. Do not freeze after reconstitution.
Quality Assurance
- Every batch ships to a ≥98% supplier batch specification
- Selected lots are independently tested by Janoshik Analytical, confirming molecular identity
- Independent test reports are searchable by batch code at certapeptides.com/verify
- EU-based quality control under CERTALAB S.R.L.
Important Notice — Research Use Only
Retatrutide is supplied by CertaPeptides strictly as a laboratory research compound. The research context described above is drawn from the published scientific literature and is reported here for background only. It is not a medical claim and does not describe what CertaPeptides' research material will do in any individual. This product is not a drug, not a dietary supplement, not a cosmetic, and not approved by the FDA, EMA, or any other regulatory authority for over-the-counter sale for human or veterinary use. It is not intended to diagnose, treat, cure, prevent, or mitigate any disease or condition. For laboratory research purposes only. Not for human consumption.
Specification Summary
About Retatrutide
What Is Retatrutide?
Retatrutide (CAS 2381089-83-2; also known as LY3437943) is a 39-amino acid synthetic peptide engineered as a triple agonist of three distinct metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG). Its structure carries a C-20 fatty diacid conjugated to the peptide backbone, extending the plasma half-life. CertaPeptides supplies retatrutide in lyophilized powder form from 2mg through 60mg per vial.
CAS: 2381089-83-2. Alternate identifier: LY3437943. Molecular weight: 4703.5 g/mol. Receptor-engagement profile: GIP-R, GLP-1R, and GCG-R simultaneously.
How Retatrutide Is Studied in the Literature
Retatrutide is characterised in the published peptide-research literature primarily through its triple-receptor pharmacology and its effects in preclinical metabolic models. The notes below describe the research context in which the molecule is investigated. They are reported for scientific background only and are not claims about what CertaPeptides' research compound will do in any individual.
Body-composition and energy-expenditure research
In preclinical and in-vitro metabolic models, retatrutide is studied for its effects on body composition, adiposity, and energy-expenditure pathways. Researchers investigate how simultaneous engagement of GIP-R, GLP-1R, and GCG-R modulates these processes relative to single- and dual-receptor agonists.
Glucose-regulation pathway research
Retatrutide is also investigated in metabolic models for its role in glucose-regulation and incretin signalling pathways, including the dose-dependent receptor pharmacology that underlies its activity at the three target receptors.
Within the Incretin Class — How Retatrutide Differs
Retatrutide is studied alongside two other research peptides in the same metabolic class: semaglutide (single GLP-1R agonist) and tirzepatide (dual GIP/GLP-1R agonist). The three differ structurally and mechanistically in ways that shape how each compound is studied:
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor engagement | GLP-1R (single) | GIP-R + GLP-1R (dual) | GIP-R + GLP-1R + GCG-R (triple) |
| Amino acid count | 31 | 39 | 39 |
| Molecular weight | 4113.58 Da | 4813.5 Da | 4703.5 Da |
| Unique mechanistic element | Fatty-acid modification extends half-life at GLP-1R | Imbalanced biased agonism favouring GIP-R | Glucagon-receptor engagement adds hepatic glucose output & energy expenditure signals |
The glucagon-receptor arm is the distinguishing feature: neither semaglutide nor tirzepatide activates GCG-R. In research contexts this is of interest because glucagon agonism increases hepatic glucose output and thermogenesis, adding an energy-expenditure component not present in the single- or dual-agonist compounds. Researchers comparing the three frequently reference the GLP-1 class comparison overview and the molecular-level triple-receptor mechanism overview.
Research Areas Where Retatrutide Is Studied
- GIP, GLP-1, and glucagon receptor pharmacology — comparative in vitro binding and signalling assays
- Preclinical metabolic models of body composition and energy expenditure
- Comparative studies against single- and dual-agonist compounds (semaglutide, tirzepatide)
- Lipid metabolism and hepatic glucose-output pathways (glucagon-arm specific)
- Formulation and stability research for long-acting peptide analogues
Specifications
| CAS Number | 2381089-83-2 |
| Alternate identifier | LY3437943 |
| Molecular Weight | 4703.5 g/mol |
| Receptor profile | Triple agonist: GIP-R / GLP-1R / GCG-R |
| Purity | ≥ 98% (supplier batch spec) |
| Physical Form | Lyophilized (freeze-dried) powder in sealed glass vial |
| Available Sizes | 2mg, 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg |
Storage
Lyophilized powder: −20°C for long-term storage. 2–8°C for short-term use before reconstitution.
Reconstituted: 2–8°C, use within 4 weeks. Do not freeze after reconstitution.
Quality Assurance
- Every batch ships to a ≥98% supplier batch specification
- Selected lots are independently tested by Janoshik Analytical, confirming molecular identity
- Independent test reports are searchable by batch code at certapeptides.com/verify
- EU-based quality control under CERTALAB S.R.L.
Important Notice — Research Use Only
Retatrutide is supplied by CertaPeptides strictly as a laboratory research compound. The research context described above is drawn from the published scientific literature and is reported here for background only. It is not a medical claim and does not describe what CertaPeptides' research material will do in any individual. This product is not a drug, not a dietary supplement, not a cosmetic, and not approved by the FDA, EMA, or any other regulatory authority for over-the-counter sale for human or veterinary use. It is not intended to diagnose, treat, cure, prevent, or mitigate any disease or condition. For laboratory research purposes only. Not for human consumption.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Iceland, Serbia). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
